Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Latigo Biotherapeutics, Inc. (LTGO)

Latigo Biotherapeutics completes $345.6 million IPO at $18.00 per share, adopts new charter

Neutral Impact 3 of 5 financing Written later

Latigo Biotherapeutics, Inc. closed its initial public offering on August 10, 2026, selling 19,200,000 shares of common stock at $18.00 per share. Gross proceeds were approximately $345.6 million before underwriting discounts, commissions and offering expenses. The company also filed an amended and restated certificate of incorporation and adopted amended and restated bylaws in connection with the closing.

Key points

  • IPO: 19,200,000 common shares sold at $18.00 per share on August 10, 2026
  • Gross proceeds of approximately $345.6 million, before underwriting discounts and expenses
  • Restated certificate of incorporation filed with the Delaware Secretary of State and restated bylaws adopted, both effective August 10, 2026
  • Full text of the restated documents filed as Exhibits 3.1 and 3.2

The filing

CompanyLatigo Biotherapeutics, Inc. (LTGO)
Form8-K, current report
Filed with the SECAug 10, 2026, 4:02 PM ET
Accession number0001193125-26-342321

Items reported: 5.03 Bylaw / Charter Amendment8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.